What is Passage Bio Inc?
, a genetic medicines company, develops gene therapies for central nervous system diseases.
The story behind the price, the case for and against, and what could go wrong. Open a part to read it.
, a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; and PBKR03, for the treatment of Krabbe disease. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 13.68M.
A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.